Effect of combined immunosuppressive anticoagulant and antiplatelet therapy of the course of chronic mesangial-proliferative glomerulonephritis.
Thirty-one patients with chronic mesangial-proliferative glomerulonephritis, histologically and clinically active, confirmed on biopsy, were included in a randomized therapeutic experiment. Of the total, 15 were treated by a combined prednisone, azathioprine, cyclophosphamide, Heparoid Spofa forte ling., Heparin retard Spofa and dipyridamole therapy. The control group comprised 16 untreated patients. One year later, a similar progression of glomerulonephritis was seen in both groups. Both treated and control patients exhibited a slight, but significant, decrease in proteinuria and a slow fall in the glomerular filtration rate. Despite a short period of follow-up, we succeeded to demonstrate, convincingly enough, that combined cyclophosphamide, azathioprine, prednisone, Heparoid ling., Heparin retard Spofa and dipyridamole therapy should not be indicated in chronic mesangial-proliferative glomerulonephritis.
D000293:Adolescent; D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D002648:Child; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005921:Glomerulonephritis / Q000188:drug therapy*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D011897:Random Allocation
D000925:Anticoagulants; D007166:Immunosuppressive Agents; D004176:Dipyridamole; D003520:Cyclophosphamide; D006493:Heparin; D001379:Azathioprine; D011241:Prednisone